Dilation

EQS-News: Bentley Endovascular Group AB brings on-board Keensight Capital, A.P. Moller Holding, and Bonit Capital as new investors

Retrieved on: 
Friday, October 27, 2023
IPO, KOREA, Catheter, Medtech, AFRICA, Health, Moyamoya disease, OR, Dilation, Growth, Marketing, Cardiology, AMERICA, Stent, Delphi, Security (finance), Financial services, Management, Cryptocurrency, Automotive industry, NEW ZEALAND

Bentley Endovascular Group AB brings on-board Keensight Capital,

Key Points: 
  • Bentley Endovascular Group AB brings on-board Keensight Capital,
    Keensight Capital (“Keensight”) invests in Bentley Endovascular Group AB (“Bentley” or “the Group”) alongside A.P.
  • The founders and management retain control and still hold the majority of the capital and the votes in the Swedish holding company Bentley Endovascular Group AB.
  • Headquartered in Stockholm, Sweden, Bentley Endovascular Group AB controls its key subsidiary Bentley InnoMed GmbH and Qmedics AG.
  • Bentley Endovascular Group AB: Stent production at the major site in Hechingen, Germany
    Bentley Endovascular Group AB: Major production site at Hechingen, Germany

Cagent Vascular announces initial RECOIL Study results: Serranator demonstrates 49% less recoil than POBA in BTK arteries

Retrieved on: 
Tuesday, July 11, 2023
Health, FDA, Surgery, Health Technology, General Health, Clinical Trials, Biotechnology, CE, Clear, Amputation, Stanford University, PAD, Fernand Serrane, Elective surgery, BTK, Sale, Peripheral artery disease, Wound healing, Patient, Risk, Mortality, CLTI, Dilation, Dissection, Telescopic sight, Medical imaging, POBA, MD

Cagent Vascular, the exclusive developer of serration technology for vessel dilatation in endovascular interventions, announced the results of its Below-the-Knee (BTK) RECOIL study.

Key Points: 
  • Cagent Vascular, the exclusive developer of serration technology for vessel dilatation in endovascular interventions, announced the results of its Below-the-Knee (BTK) RECOIL study.
  • This Core Lab-Adjudicated Recoil analysis, the first of its kind, evaluated vessel recoil in lesions treated with Serranator® verses Plain Old Balloon Angioplasty (POBA).
  • The study results demonstrated that lesions treated using Serration Angioplasty exhibited 49% less average recoil than POBA.
  • “The 49% difference demonstrated in the RECOIL study between Serranator® and POBA is statistically significant and in my view also clinically relevant.

Pharmazz Inc. Announces Key Publications Regarding the Role of Adrenergic Receptors in Venous Blood Return to Treat Shock

Retrieved on: 
Monday, March 20, 2023
Blood pressure, Heart, Frontiers Media, Therapy, Journal of Clinical Medicine, Food and Drug Administration, Shock, Artery, Hypovolemic shock, Person, Alpha-1 adrenergic receptor, Medicine, Intensive care medicine, Journal, Publication, International Symposium on Endovascular Therapy, Patient, Standard of care, Mortality, Nursing care plan, FDA, Dilation, Food, Safety, Nursing, Pharmaceutical industry, Phase, Physiology

WILLOWBROOK, Ill., March 20, 2023 (GLOBE NEWSWIRE) -- Pharmazz, Inc. (“Pharmazz”), a biopharmaceutical company focused on developing and commercializing novel therapeutics to treat patients in critical care, announced two key publications. These publications further our understanding of adrenergic receptors in treating shock. A free version of the article published in the Journal of Clinical Medicine is available at: https://www.mdpi.com/2077-0383/12/3/1108. Controls of central and peripheral blood pressure are critical in treating patients with hemorrhagic/hypovolemic shock. It has been demonstrated that alpha2-adrenergic receptors could be a suitable target for managing hypovolemic shock. Centhaquine is the Company’s alpha2 adrenergic receptor agonist that showed an absolute 8.8 percent reduction in 28-day all-cause mortality in Phase III clinical trial for hypovolemic shock conducted in India.

Key Points: 
  • These publications further our understanding of adrenergic receptors in treating shock.
  • Controls of central and peripheral blood pressure are critical in treating patients with hemorrhagic/hypovolemic shock.
  • It has been demonstrated that alpha2-adrenergic receptors could be a suitable target for managing hypovolemic shock.
  • Another article published in Frontiers in Physiology, titled Role of adrenergic receptors in shock,” highlights that centhaquine (Lyfaquin®) increases cardiac preload by activating alpha2B adrenergic receptors to increase venous blood return to the heart and decreases cardiac afterload by activating alpha2A adrenergic receptors to decrease sympathetic drive and dilatation of arteries.

Ancora Heart Announces Late-Breaking Clinical Science Presentation Among Key Activities at Technology and Heart Failure Therapeutics Conference

Retrieved on: 
Tuesday, March 14, 2023
Surgery, Hospitals, Clinical Trials, Health Technology, Cardiology, Biotechnology, Health, Pharmaceutical, General Health, HF, Heart failure, Dilation, THT, CRF, Patient, Therapy, Heart, Pharmaceutical industry, Nightclub

Ancora Heart, Inc., a company developing a novel device-based therapy to address heart failure (HF), today announced that a late-breaking clinical science presentation featuring the latest data from studies of the investigational AccuCinch® Ventricular Restoration System will take place at the upcoming Technology and Heart Failure Therapeutics conference (THT 2023).

Key Points: 
  • Ancora Heart, Inc., a company developing a novel device-based therapy to address heart failure (HF), today announced that a late-breaking clinical science presentation featuring the latest data from studies of the investigational AccuCinch® Ventricular Restoration System will take place at the upcoming Technology and Heart Failure Therapeutics conference (THT 2023).
  • This event is produced by the Cardiovascular Research Foundation (CRF) and will be held March 20 - 22 at the Westin Boston Seaport in Boston, Mass.
  • The late-breaking clinical science from Ancora Heart will be presented by Dr. Nadira Hamid, interventional echocardiographer, cardiologist at Allina Health Minneapolis Heart Institute and assistant director of the echocardiographic core lab CRF.
  • The data will include complete 12-month clinical outcomes from an analysis of 51 symptomatic heart failure patients with reduced ejection fraction (HFrEF) who were treated with the AccuCinch System.

EQS-News: Tennant Minerals continues success streak of ultra-high-grade copper-gold results

Retrieved on: 
Monday, February 13, 2023
Copper, FRA, Sulfide, IP, News, TMS, Dilation, ESG, Publication, RADIUS, Gold, CU, Risk, Acquisition, Tennant Creek, ASX, Magnetism, Security (finance), Lithium, Perseverance, Bluebird

Australian copper-gold explorer Tennant Minerals (ASX: TMS; FRA: UH7A) continues its run of spectacularly high-grade drill results.

Key Points: 
  • Australian copper-gold explorer Tennant Minerals (ASX: TMS; FRA: UH7A) continues its run of spectacularly high-grade drill results.
  • Tennant is planning new drilling to test the surface extensions of this exceptionally thick and high-grade copper-gold zone as well as at depth.
  • With a discovery outside Bluebird, Tennant would reach a size potential that would undoubtedly be of interest to larger resource companies.
  • Further more there is a consulting or other service contract between Tennant Minerals and GOLDINVEST Consulting GmbH, which means that a conflict of interest exists.

PTA Balloon Catheter Market Report 2022: Increasing Prevalence of Cardiovascular Disease Drives Growth - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 8, 2022
Health, Surgery, Cardiology, Medical Devices, Degenerative disease, Arm, Leg, Medtronic, Boston Scientific, CVD, Cardinal Health, Global Health, Skin, Prevalence, Dilation, US, BD (company), PTA, LASI, Femoral artery, Death, Circulatory system, Growth, Application, Marketing, Region, Radial artery, Cardiovascular disease, Cook Group, Renewable energy, Pharmaceutical industry, Synthetic rubber

The "PTA Balloon Catheter Market, by Material Type, by Application, by End User, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "PTA Balloon Catheter Market, by Material Type, by Application, by End User, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030" report has been added to ResearchAndMarkets.com's offering.
  • PTA balloon catheter is an innovative medical device, which is inserted in the femoral artery in the leg or sometimes into the radial artery in the arm for the treatment of constricted blood vessels.
  • As the balloon inflates, the cage causes the balloon to form a series of segmented pillows and grooves along the entire lesion.
  • The standard PTA balloon catheter segment has represented the largest share of the total PTA balloon catheter market.

Continued Clinical Success Reported with Unique Cutting-Edge Vessel Prep Device

Retrieved on: 
Thursday, June 30, 2022
CE marking, Fistula, FDA, Tri-City Medical Center, View, Patient, PTA, Multimedia, Hyperplasia, Angioplasty, CE, Dissection, Technology, Dural arteriovenous fistula, CS, PARK, XO, ATM, Dilation, Stenosis, Aluminium, Natural rubber, Medical device

PARK CITY, Utah, June 30, 2022 /PRNewswire/ -- Transit Scientific shares successful outcomes on multiple fistula and graft cases using its XO Score Sheath Platform along with off-the-shelf percutaneous transluminal angioplasty (PTA) balloons.

Key Points: 
  • First-of-its-kindmetal-alloy scoring, cutting, and constraining structure (CS) device continues to elevate angioplasty treatment of chronic dialysis fistulas and grafts.
  • The lesion was resistant to initial treatment using a high-pressure PTA inflated to 40 atmospheres (ATM).
  • The lesion was then treated with the XO Scoredevice and followed by effacement of the stenosis with standard balloon PTA inflated to nominal pressure (9ATM).
  • When the angioplasty balloon is inflated, the struts/grooves expand with the balloon and rotate 90 to apply focal force to the vessel.

Endpoint Health Announces Results from Retrospective Analyses Evaluating the Corticosteroid Response in Patients with Septic Shock, Based on Novel Gene Expression Scoring Model

Retrieved on: 
Wednesday, March 2, 2022
Health, Genetics, Research, Pharmaceutical, Science, Biotechnology, Division, High-dependency unit, Therapy, Social media, Data, Critical care, Twitter, Distributive shock, Vasodilatory shock, BMJ Open, RNA, Septic shock, Diagnosis, Gene, Social, Hydrocortisone, Inflammatory bowel disease, Biology, Vasodilation, Safety, Disease, Food, Acute respiratory distress syndrome, Gene expression, Machine learning, Critical Care Medicine (journal), Blood pressure, Rheumatoid arthritis, United, FDA, US Foods, Blood, Patient, MD, Research, Health, Shock, Mortality, Intensive care unit, Dilation, Medical device, Pharmaceutical industry, SHOCK, Norepinephrine, Sepsis, Medscape, Burn, the Research, Septic Shock, Endpoint Health, Health, Genetics, Research, Pharmaceutical, Science, Biotechnology, the Research, Septic Shock, Endpoint Health, THE RESEARCH, SEPTIC SHOCK, ENDPOINT HEALTH

This research is a meaningful step towards exploring the possibility that subgroups of septic shock patients may respond differently to hydrocortisone therapy depending on their biological characteristics.

Key Points: 
  • This research is a meaningful step towards exploring the possibility that subgroups of septic shock patients may respond differently to hydrocortisone therapy depending on their biological characteristics.
  • These latest findings further illustrate the potential of our proprietary AI and machine learning platform to inform personalized care for critically ill patients, based on electronic health data and gene expression scoring.
  • To identify unique biological subgroups of patients, the researchers conducted a retrospective analysis, pooling publicly available data from various gene expression datasets of patients with sepsis and septic shock.
  • The secondary outcome was the immunological response to hydrocortisone therapy.1 This outcome was assessed based on gene expression data from the Burn study.

Four More Late-Breaking Clinical Trials Announced at VIVA21

Retrieved on: 
Tuesday, October 5, 2021
Thrombosis, VIVA, National Heart, Lung, and Blood Institute, Standard of care, Patient, International Society on Thrombosis and Haemostasis, PE, CT, Boston Scientific, Pulmonary artery, Adult, Genentech, International Society, Organic, The Rheumatoid Arthritis Quality of Life Questionnaire, Bashir, BEC, CTA, Ageing, Dilation, EKOS, National Heart Valve Disease Awareness Day, Male, Bleeding, Thrombus, Research, Safety, Quality of life, Miller, Blood vessel, Lung, Wynn Las Vegas, Education, Medical imaging, Pharmaceutical industry, Medical device

Patients with acute intermediatehigh-risk or high-risk PE and treated with EKOS acoustic pulse thrombolysis were enrolled between March 2018 and June 2020.

Key Points: 
  • Patients with acute intermediatehigh-risk or high-risk PE and treated with EKOS acoustic pulse thrombolysis were enrolled between March 2018 and June 2020.
  • Patients with symptomatic obstruction of one iliofemoral venous segment were enrolled (ie, CEAP [clinical, etiology, anatomy, pathophysiology] clinical classification 3 or Venous Clinical Severity Score [VCSS] pain score 2).
  • Clinical improvement, as measured by VCSS, VDS, CEAP "C", and CIVIQ, was sustained through 3 years (P
  • In conclusion, the 3-year results of the VIVO clinical study support the continued safety and effectiveness of the Zilver Vena venous stent.

Tenax Announces New Publication Highlighting Novel Levosimendan Mechanism of Action in Pulmonary Hypertension Patients with Heart Failure and Preserved Ejection Fraction (PH-HFpEF)

Retrieved on: 
Thursday, August 12, 2021
Health, Practice Management, Fitness & Nutrition, General Health, Pharmaceutical, Cardiology, SEC, PDGF, Population, Therapy, Pulmonary wedge pressure, Tenax, Annual report, Company, U.S. Securities and Exchange Commission, Research, Orion Corporation, Heart Failure Society of America, Trial of the century, Blood, HELP, Heart, Journal, List of The 4400 characters, Security (finance), Pulmonary hypertension, Private Securities Litigation Reform Act, Goal, CVP, MD, Acute leukemia, Exercise, Central venous pressure, Stomach, PCWP, SBV, Nasdaq, Imatinib, Heart failure with preserved ejection fraction, BCR, News, Dilation, Heart failure, CEO, KOL, Hemodynamics, Webcast, Form 10-K, Form, Compliance, Splanchnic, Journal of Cardiac Failure, Review, Patient, Pharmaceutical industry, Medical imaging, Tenax Therapeutics, Levosimendan, Imatinib, TENAX THERAPEUTICS, LEVOSIMENDAN, IMATINIB

The HELP Study evaluated levosimendan in patients with pulmonary hypertension and heart failure with preserved ejection fraction (PH-HFpEF).

Key Points: 
  • The HELP Study evaluated levosimendan in patients with pulmonary hypertension and heart failure with preserved ejection fraction (PH-HFpEF).
  • The new publication, Changes in Stressed Blood Volume with Levosimendan in Pulmonary Hypertension from Heart Failure with Preserved Ejection Fraction: Insights Regarding Mechanism of Action appears in the Journal of Cardiac Failure.
  • Chris Giordano, CEO of Tenax Therapeutics, stated, This publication shares new, and very important mechanistic knowledge about the effects of levosimendan in PH-HFpEF patients.
  • It initially was developed as an inotrope for intravenous use in hospitalized patients with acutely decompensated heart failure.